BiotechTube

LX1001

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

May 8, 2023 → Nov 1, 2028

NCT ID
NCT05400330

About LX1001

LX1001 is a phase 1 stage product being developed by Lexeo Therapeutics for Alzheimer Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05400330. Target conditions include Alzheimer Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)
✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
✅DonepezilEisaiApproved
✅DONEPEZIL HYDROCHLORIDEEisaiApproved
✅Donepezil HCLEisaiApproved
✅Donepezil HClEisaiApproved
✅Donepezil HydrochlorideEisaiApproved
✅AriceptEisaiApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05400330Phase 1Active
NCT03634007Phase 1/2Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
Zagotenemab + PlaceboEli LillyPhase 2
35
Donanemab + Placebo + LY3202626Eli LillyPhase 2
35
Donanemab + PlaceboEli LillyPhase 3
47
GSK4527226AlectorPhase 2
29
AL002 + PlaceboAlectorPhase 2
25
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
donanemabEli LillyPhase 2
35
ATH-1017LeonaBioPhase 2/3
20
ATH-1017 + PlaceboLeonaBioPhase 2/3
28
ATH-1017 + PlaceboLeonaBioPhase 2
25
NDX-1017 + PlaceboLeonaBioPhase 1
19
simufilamCassava SciencesPhase 2
17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
19